# Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer

Source: https://onco.cc/trials/nct07522151/  
OnCo record `nct07522151` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Adebrelimab and Oxaliplatin in gastric & gastro-oesophageal junction cancer, run by Shanghai Shengdi Pharmaceutical Co., Ltd, now recruiting.

## Summary

Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer is a phase 3 interventional study registered as NCT07522151 by Shanghai Shengdi Pharmaceutical Co., Ltd, with 874 participants planned, started 2026-05-07 and due to reach its primary completion in 2029-12. Interventions recorded: Adebrelimab plus S-1 and oxaliplatin and Adebrelimab blank preparation plus S-1 and oxaliplatin..

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07522151
- Phase: 3
- Setting: A Randomized, Double-blind, Multicenter Phase III Trial of Adebrelimab (SHR-1316) Plus S-1 and Oxaliplatin (SOX) Versus Placebo Plus S-1 and Oxaliplatin in the Perioperative Treatment of Resectable Gastric or Gastroesophageal Junction Cancer
- Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd
- Enrolled: 874

## Sources

- ClinicalTrials.gov NCT07522151: https://clinicaltrials.gov/study/NCT07522151

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07522151.json